Abstract
PP01.99 Switching to Subcutaneous (SC) Atezolizumab After Intravenous (IV) Dosing: Evaluation of Atezolizumab Pharmacokinetics (PK) Using Population PK Modeling
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have